# Dolutegravir Pediatric Liquid Formulation Study

> **NCT03921723** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 22 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Dolutegravir dispersible tablet
- **DRUG:** Dolutegravir oral suspension
- **DRUG:** Dolutegravir oral solution

## Key facts

- **NCT ID:** NCT03921723
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2019-07-25
- **Final completion:** 2019-07-25
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03921723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03921723, "Dolutegravir Pediatric Liquid Formulation Study". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03921723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*